Clinical Trial Update: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with dual anti-HER2 blockade (trastuzumab and pertuzumab) in early breast cancer with HER2-enriched subtype; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED